Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Identifieur interne : 000420 ( Main/Exploration ); précédent : 000419; suivant : 000421Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Auteurs : Paul Emery [Royaume-Uni] ; Anthony Sebba [États-Unis] ; Tom W J. Huizinga [Pays-Bas]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-12.
Abstract
Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy. Additionally, an analysis of healthcare claims data showed that when MTX was prescribed in conjunction with a biologic agent, as many as 58% of patients did not collect the MTX prescription. Given this discrepancy between perception and real life, we conducted a review of the peer-reviewed literature and rheumatology medical congress abstracts to determine whether data support biologic monotherapy as a treatment option for patients with rheumatoid arthritis. Our analysis suggests only for tocilizumab is there evidence that the efficacy of biologic monotherapy is comparable with combination therapy with MTX.
Url:
DOI: 10.1136/annrheumdis-2013-203485
Affiliations:
- Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Floride, Hollande-Méridionale, Yorkshire-et-Humber
- Leeds, Leyde, Tampa
- Université de Floride du Sud, Université de Leeds
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B99
- to stream Istex, to step Curation: 000B98
- to stream Istex, to step Checkpoint: 000076
- to stream Main, to step Merge: 000420
- to stream Main, to step Curation: 000420
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis</title><author><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name></author><author><name sortKey="Sebba, Anthony" sort="Sebba, Anthony" uniqKey="Sebba A" first="Anthony" last="Sebba">Anthony Sebba</name></author><author><name sortKey="Huizinga, Tom W J" sort="Huizinga, Tom W J" uniqKey="Huizinga T" first="Tom W J" last="Huizinga">Tom W J. Huizinga</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6BDDCA238719E6A0A2057D1F6D9DE507038B9C87</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-203485</idno><idno type="url">https://api.istex.fr/document/6BDDCA238719E6A0A2057D1F6D9DE507038B9C87/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B99</idno><idno type="wicri:Area/Istex/Curation">000B98</idno><idno type="wicri:Area/Istex/Checkpoint">000076</idno><idno type="wicri:doubleKey">0003-4967:2013:Emery P:biologic:and:oral</idno><idno type="wicri:Area/Main/Merge">000420</idno><idno type="wicri:Area/Main/Curation">000420</idno><idno type="wicri:Area/Main/Exploration">000420</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis</title><author><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds</wicri:regionArea><orgName type="university">Université de Leeds</orgName><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust United Kingdom, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="Sebba, Anthony" sort="Sebba, Anthony" uniqKey="Sebba A" first="Anthony" last="Sebba">Anthony Sebba</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Rheumatology, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Huizinga, Tom W J" sort="Huizinga, Tom W J" uniqKey="Huizinga T" first="Tom W J" last="Huizinga">Tom W J. Huizinga</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Rheumatology, Leiden University Medical Center, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-12">2013-12</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1897">1897</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">6BDDCA238719E6A0A2057D1F6D9DE507038B9C87</idno><idno type="DOI">10.1136/annrheumdis-2013-203485</idno><idno type="href">annrheumdis-72-1897.pdf</idno><idno type="ArticleID">annrheumdis-2013-203485</idno><idno type="PMID">23918035</idno><idno type="local">annrheumdis;72/12/1897</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Clinical evidence demonstrates coadministration of tumour necrosis factor inhibitor (TNFi) agents and methotrexate (MTX) is more efficacious than administration of TNFi agents alone in patients with rheumatoid arthritis, leading to the perception that coadministration of MTX with all biologic agents or oral disease-modifying antirheumatic drugs is necessary for maximum efficacy. Real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy. Additionally, an analysis of healthcare claims data showed that when MTX was prescribed in conjunction with a biologic agent, as many as 58% of patients did not collect the MTX prescription. Given this discrepancy between perception and real life, we conducted a review of the peer-reviewed literature and rheumatology medical congress abstracts to determine whether data support biologic monotherapy as a treatment option for patients with rheumatoid arthritis. Our analysis suggests only for tocilizumab is there evidence that the efficacy of biologic monotherapy is comparable with combination therapy with MTX.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Floride</li><li>Hollande-Méridionale</li><li>Yorkshire-et-Humber</li></region><settlement><li>Leeds</li><li>Leyde</li><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li><li>Université de Leeds</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name></region><name sortKey="Emery, Paul" sort="Emery, Paul" uniqKey="Emery P" first="Paul" last="Emery">Paul Emery</name></country><country name="États-Unis"><region name="Floride"><name sortKey="Sebba, Anthony" sort="Sebba, Anthony" uniqKey="Sebba A" first="Anthony" last="Sebba">Anthony Sebba</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Huizinga, Tom W J" sort="Huizinga, Tom W J" uniqKey="Huizinga T" first="Tom W J" last="Huizinga">Tom W J. Huizinga</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6BDDCA238719E6A0A2057D1F6D9DE507038B9C87
|texte= Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.25. |  |